SUVEN LIFE SCIENCES LTD.

Suven Life Sciences announced positive outcomes from an independent Data and Safety Monitoring Board (DSMB) review and a pre-specified Interim Analysis of its ongoing global Phase 3 study for Masupirdine (SUVN-502) in Alzheimer's Disease agitation. The DSMB recommended the trial continue as planned with no modifications, identifying no safety concerns. An interim analysis also supported continuing without increasing the sample size. Enrollment is at 88%, with completion expected by September 2026, and top-line results anticipated in Q2-2027.

Suven Life Sciences Ltd received a rectification order from the Income Tax Department for the assessment year 2020-21. The order pertains to the disallowance of weighted deduction claimed under section 35 (2AB) of the Income Tax Act, 1961, due to the absence of approval from the Department of Scientific and Industrial Research (DSIR) in Form No. 3CL. The company has already responded, stating reasons to drop the notice. Suven Life Sciences plans to appeal the order and does not anticipate any material impact on its financials or operations.

Suven Life Sciences Ltd. has issued a clarification regarding recent volume movement in its stock. The company stated that it has been diligently disclosing all material events and information as required under Regulation 30 of the SEBI (LODR) Regulations, 2015. Currently, there are no undisclosed material events that could be influencing the stock's price or volume. The company believes the recent price and volume fluctuations are due to market speculation and has no further comments. Suven Life Sciences has requested the dissemination of this clarification to the public.

Suven Life Sciences Ltd has released the Monitoring Agency Report by CRISIL Ratings Limited for the quarter ended March 31, 2026, concerning the utilization of proceeds from the Preferential Issue. The report, issued in compliance with SEBI regulations, confirms no deviations from the intended objectives of the issue. CRISIL Ratings declares an objective view based on provided information, disclaiming audit responsibilities and liability for losses from the report's use.

Suven Life Sciences Ltd has granted 1,33,200 stock options to eligible employees under the 'Suven Life Employee Stock Option Scheme 2020' (SLSL ESOP 2020). The grant, approved on May 13, 2026, allows employees to apply for equity shares of ₹1 each at an exercise price of ₹55 per option. The options will vest over three years, starting May 13, 2027, with a two-year exercise period from the vesting date. The Nomination & Remuneration Committee retains the right to modify the vesting schedule, subject to applicable laws.

Suven Life Sciences Ltd's Board Meeting on May 13, 2026, approved audited financial results for the year ended March 31, 2026, reporting a net loss of ₹5,486.28 lakhs. The board also approved the notice for the 37th Annual General Meeting scheduled for August 25, 2026, via video conferencing. Additionally, the board noted the acceptance of waiver of fines by BSE and advised management to ensure strict compliance with SEBI regulations.

Suven Life Sciences Ltd's board meeting on May 13, 2026, approved audited financial results for the year ended March 31, 2026. The company reported a net loss of ₹5,486.28 lakhs for the year. The board also approved the notice for the 37th Annual General Meeting scheduled for August 25, 2026, via video conferencing. Additionally, the board noted the acceptance of waiver of fines by BSE and advised management to ensure strict compliance with SEBI regulations.

Suven Life Sciences announced that its Global Phase 3 trial of Masupirdine (SUVN-502) for agitation in Alzheimer’s dementia has reached a 76% enrollment milestone. The 375-patient study (NCT05397639, EudraCT Number 2021-003405-22) is being conducted across North America and Europe. The company anticipates completing patient enrollment by the end of 2026, with data readout expected by April 2027. Masupirdine is a selective 5-HT6 receptor antagonist aimed at treating agitation in Alzheimer's patients.

Suven Life Sciences Ltd has scheduled a Board of Directors meeting on May 13, 2026, to consider and approve the audited financial results for the quarter and financial year ended March 31, 2026. The trading window was closed from April 1, 2026, and will remain closed until 48 hours after the declaration of the financial results, i.e., May 15, 2026.

Suven Life Sciences Ltd has clarified that they have notified all events that come under the purview of Regulation 30 of SEBI (LODR) Regulations, 2015. They currently do not have any material announcements or events that may affect the price or volume behavior of the scrip. The recent price/volume movement is attributed to market speculation.